恩瑞格服用说明

(sold under the trade names Exjade, Desirox, Defrijet, Desifer, Rasiroxpine, and Jadenu) are oral iron chelators. Its primary use is to reduce chronic iron overload in patients receiving chronic transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral drug approved for this purpose in the United States. It was approved by the U.S. Food and Drug Administration (FDA) in November 2005. According to the FDA (May 2007), renal failure and cytopenias have been reported in patients receiving Enrigor oral suspension tablets. It is approved in the EU by the European Medicines Agency (EMA) for patients aged 6 years and older with chronic iron overload from repeated blood transfusions.

Enrige dispersible tablets should be taken on an empty stomach at least 30 minutes before meals, once a day, preferably at the same time every day. Tablets should not be chewed or swallowed whole. Enrig dispersible tablets should not be taken together with aluminum-containing antacids, and the dosage (mg/kg) needs to be calculated and rounded to the nearest whole tablet. Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before being taken. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion.

Enriga may cause gastrointestinal dysfunction, rash, mild elevation of serum creatinine, transaminases and other problems. Therefore, it is recommended that patients take medicines under the guidance of a doctor and avoid overuse. The affinity of Enrige dispersible tablets to zinc and copper is very low, but the concentrations of these trace metals in the serum still decrease to varying degrees after administration.

Drug overdose: 1. Cases of drug overdose (taking 2-3 times the prescribed dose for several weeks) have been reported. One case report reported that an overdose resulted in subclinical hepatitis, which resolved after discontinuation of the drug, with no long-term effects. 2. Thalassemia patients with iron overload can tolerate a single dose of 80 mg/kg with only mild nausea and diarrhea. 3. A single dose of 40mg/kg can be well tolerated by healthy volunteers. 4. Signs of acute overdose include nausea, vomiting, headache and diarrhea. Treatment of overdose includes induction of vomiting, gastric lavage, and symptomatic treatment.